| Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual {beta}-Cell Function. | |
| | |
MedLine Citation:
|
PMID: 21593296 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual β-cell function. RESEARCH DESIGN AND METHODS Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied. All C-peptide-positive patients were treated with liraglutide plus insulin, whereas C-peptide-negative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy. Continuous glucose monitoring with identical food intake and physical activity was performed before (week 0) and during (week 4) treatment. Differences in insulin dose; HbA(1c); time spent with blood glucose <3.9, >10, and 3.9-9.9 mmol/L; and body weight were evaluated. RESULTS Insulin dose decreased from 0.50 ± 0.06 to 0.31 ± 0.08 units/kg per day (P < 0.001) in C-peptide-positive patients and from 0.72 ± 0.08 to 0.59 ± 0.06 units/kg per day (P < 0.01) in C-peptide-negative patients treated with liraglutide but did not change with insulin monotherapy. HbA(1c) decreased in both liraglutide-treated groups. The percent reduction in daily insulin dose was positively correlated with β-cell function at baseline, and two patients discontinued insulin treatment. In C-peptide-positive patients, time spent with blood glucose <3.9 mmol/L decreased from 3.0 to 1.0 h (P = 0.03). A total of 18 of 19 patients treated with liraglutide lost weight during treatment (mean [range] -2.3 ± 0.3 kg [-0.5 to -5.1]; P < 0.001). Transient gastrointestinal adverse effects occurred in almost all patients treated with liraglutide. CONCLUSIONS Treatment with liraglutide in type 1 diabetic patients reduces insulin dose with improved or unaltered glycemic control. |
| | |
Authors:
|
Urd Kielgast; Thure Krarup; Jens Juul Holst; Sten Madsbad |
Related Documents
:
|
2649326 - Behavioral strategies for weight reduction in obese type ii diabetic patients. 10947876 - The role of habitual snoring and obesity in the development of diabetes: a 10-year foll... 18421276 - 11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negati... 15277386 - Interactions between endothelin and nitric oxide in the regulation of vascular tone in ... 18285556 - Berberine and its more biologically available derivative, dihydroberberine, inhibit mit... 15573846 - Glucose tolerance in pregnant women with vaginal candidiasis. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-5-18 |
Journal Detail:
|
Title: Diabetes care Volume: - ISSN: 1935-5548 ISO Abbreviation: - Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-5-19 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7805975 Medline TA: Diabetes Care Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Endocrinology, Hvidovre University Hospital, Copenhagen, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Effect of Zoledronic Acid on the Clinical Resolution of Charcot Neuroarthropathy: A pilot random...
Next Document: Loss of Receptor for Advanced Glycation End Products (RAGE) Defense: A cause of Charcot neuroarthrop...